Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. The company focuses on developing innovative RNA-based therapies for cardiomyopathies.

Phlox Therapeutics

Phlox Therapeutics | 705 followers on LinkedIn. RNA&#39;s to rescue cardiomyopathies | Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations.

Cardiologist at University of Amsterdam, Medical Advisor at ARMGO Pharma and CMO at Phlox Therapeutics, advisor to Forbion

Yigal Pinto

Investment Manager at UvA AMC HvA Ventures Holding BV

Ross Gordon

Principal at BGV (BioGeneration Ventures)

Rianne Ellenbroek

Prof. Molecular Cardiology UMCU and Group leader, Hubrecht Institute KNAW

Eva van Rooij

We are very exited to announce that Phlox Therapeutics has secured 1.9M seed funding to drive forwards our mission to develop RNA therapies for rare genetic laminopathies. This round of funding will be instrumental in advancing the preclinical development of our lead program, bringing us one step closer to delivering life-changing treatments for patients with genetic cardiomyopathies. A hugh thank you to our investor syndicate, including ROM Utrecht Region , UvA - Amsterdam UMC - HvA Ventures Holding BV , Utrecht Holdings Seed Fund and FIRST fund , managed by BGV (BioGeneration Ventures) for their confidence and support in our vision. At Phlox, we are committed to pioneering innovative RNA-based approaches to address critical unmet needs in cardiovascular health. With this funding, we are energized to make substantial strides toward developing new treatment options that could transform the lives of those affected by cardiomyopathies. For more information, please see the press release: https://lnkd.in/dZSHEi8x

Exciting update from our CSO, Eva van Rooij ! Demonstrating the potential of gene therapy in treating cardiomyopathies, her research group's latest publication in Nature Cardiovascular Research highlights promising outcomes of PKP2 replacement in arrhythmogenic cardiomyopathy. Read more: https://lnkd.in/d-7XnWrV

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 14, 2024 12:40 AM	daf7b0f6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 14, 2024 12:40 AM	d5716d98
crunchbase trigger	general	Nov 14, 2024 12:40 AM	a6e5569d
crunchbase profile	general
li profile	general	Nov 14, 2024 12:40 AM	1a9189f2
translate crunchbase fundingrounds	general
peers	general	Nov 14, 2024 12:40 AM	8eff6cad
news basic	general	Nov 14, 2024 12:40 AM	cece8259
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

PHLO

COM:PHLOXTHERAPEUTICS

Phlox Therapeutics